GHRH plus arginine and arginine administration evokes the same ratio of GH isoforms levels in young patients with Prader-Willi syndrome. (April 2018)

• Record Type: Journal Article
• Authors: Rigamonti, Antonello E.; Crinò, Antonino; Bocchini, Sarah; Convertino, Alessio; Bidlingmaier, Martin; Haenelt, Michael; Tamini, Sofia; Cella, Silvano G.; Grugni, Graziano; Sartorio, Alessandro
• Is Part Of: Growth hormone & IGF research. Volume 39(2018)
• Page Start: 13
• Page End: 18
• Publication Date: 2018-04
• Subjects: PWS Prader-Willi syndrome -- GHRH GH releasing hormone -- ARG arginine -- kDa kiloDalton -- BMI body mass index -- sds standard deviation score -- mAb monoclonal antibody -- CV coefficient of variation -- IGFBP-3 IGF binding protein 3; GH isoforms -- Prader-Willi syndrome -- GH deficiency -- GHRH plus arginine -- Arginine; Growth regulators -- Periodicals; Growth -- Regulation -- Periodicals; Somatomedin -- Periodicals; Somatomedins -- Periodicals; Growth Hormone -- Periodicals; Growth Substances -- Periodicals; Croissance -- Régulation -- Périodiques; Croissance -- Régulateurs -- Périodiques; Somatotrophine -- Périodiques; Somatomédine -- Périodiques; Growth -- Regulation; Growth regulators; Electronic journals; Periodicals; Electronic journals; 612.4
• DOI: 10.1016/j.ghir.2017.11.005
• Languages: English
• ISSNs: 1096-6374

Abstract

Abstract: Human GH is present in pituitary and circulation as several isoforms, the prevalent being 22 kDa- and 20 kDa-GH. Recently, we have demonstrated the preservation of a normal balance in GH isoforms after GH releasing hormone (GHRH) plus arginine (ARG) administration in adult patients with Prader-Willi syndrome (PWS), one of the most common causes of syndromic obesity, often associated with GH deficiency (GHD). Aim of the present study was to measure circulating levels of 22 kDa- and 20 kDa-GH in young PWS patients (n = 24; F/M: 10/14; genotype UPD/DEL/met +: 11/11/2; age: 10.8 ± 5.3 years; BMI SDS: 2.0 ± 2.0; GHD: 16/24; obesity: 12/24) after combined GHRH + ARG or ARG administration. The results were analysed subdividing the GHRH + ARG and ARG groups on the basis of PWS genotype, GHD status and obesity. Circulating levels of 22 kDa- and 20 kDa-GH were measured by a chemiluminescent or fluorescent method based on specific pairs of monoclonal antibodies. GHRH + ARG or ARG significantly stimulated the secretion of 22 kDa-GH but not that of 20 kDa-GH in all PWS patients. No significant GHRH + ARG- vs. ARG-induced changes in the ratios of 22 kDa- to 20 kDa-GH peaks were observed in all PWS patients, although 22 kDa- or 20 kDa-GH peaks were significantly higher in the GHRH + ARG than ARG group. When subdividing PWS patients in UPD vs. DEL, obese vs. non obese and GHD vs. non GHD subgroups, GH peaks were significantly higher in nonobese than obese patients and in non GHD than GHD patients administered with either GHRH + ARG or ARG test, apart from the comparisons in the DEL/UPD subgroups. Anyway, the ratios of peak levels of 22 kDa- to 20 kDa-GH were similar after GHRH + ARG vs. ARG in all subgroups investigated. In conclusion, this study shows that administration of two different pharmacological tests, i.e. ARG, capable of reducing hypothalamic somatostatinergic tone, and GHRH (+ ARG), that directly acts at pituitary level on the somatotropic cell, evokes the same ratios of GH isoforms in young PWS patients, suggesting that the hypothalamic dysfunction in this genetic disorder does not alter the qualitative and quantitative composition of GH isoforms present in circulation. Highlights: We carried out a research in patients with a rare disease, i.e. Prader-Willi syndrome (PWS); the topic regarding GH isoforms is of great interest, being unknown the origin of the GH deficiency in PWS; administration of two different pharmacological tests (ARG and GHRH + ARG) evokes the same ratios of GH isoforms in PWS; the (alleged) hypothalamic dysfunction in PWS does not alter the qualitative and quantitative composition of GH isoforms.